Trent S, Kong A, Short S C, Traish D, Ashley S, Dowe A, Hines F, Brada M
Neuro-Oncology Unit, The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey, UK.
J Neurooncol. 2002 May;57(3):247-51. doi: 10.1023/a:1015788814667.
Temozolomide, an imidazotetrazine prodrug has shown activity in phase II studies in patients with high-grade glioma at first recurrence. We assessed the efficacy of temozolomide as second-line therapy following failure of PCV chemotherapy in patients with recurrent/progressive gliomas.
Between September 1994 and November 2000, 32 patients with high-grade gliomas at second recurrence/progression received temozolomide as salvage therapy and results were reviewed retrospectively.
Of 32 assessable patients 7 had clinical improvement; there were no imaging responses. Median survival of the cohort was 4 months, with 28% alive at 6 months. Age, performance status, histology and previous response to PCV chemotherapy did not predict for clinical response to temozolomide.
In the small cohort of patients with recurrent malignant glioma who failed PCV chemotherapy temozolomide demonstrated limited activity as second-line treatment although this remains within the confidence intervals of response seen in patients with glioblastoma.
替莫唑胺，一种咪唑并四嗪前体药物，在首次复发的高级别胶质瘤患者的II期研究中显示出活性。我们评估了替莫唑胺作为复发性/进展性胶质瘤患者PCV化疗失败后的二线治疗的疗效。
1994年9月至2000年11月期间，32例处于第二次复发/进展期的高级别胶质瘤患者接受替莫唑胺作为挽救治疗，并对结果进行回顾性分析。
在32例可评估患者中，7例有临床改善；无影像学反应。该队列的中位生存期为4个月，6个月时28%存活。年龄、体能状态、组织学以及既往对PCV化疗的反应均不能预测对替莫唑胺的临床反应。
在PCV化疗失败的复发性恶性胶质瘤小队列患者中，替莫唑胺作为二线治疗显示出有限的活性，尽管这仍在胶质母细胞瘤患者所见反应的置信区间内。
Zotero 插件